Kevin's questions to Sarepta Therapeutics Inc (SRPT) leadership • Q3 2024
Question
Kevin, on behalf of Brian Abrahams at RBC Capital Markets, inquired about progress with payers on broader coverage policies for ELEVIDYS, particularly regarding Medicaid, and asked for the estimated proportion of Duchenne patients covered by Medicaid.
Answer
President and CEO Doug Ingram stated that the patient split is roughly 50% commercial and 50% Medicaid. He described interactions with both payer types as very productive, benefiting from extensive clinical data, Sarepta's deep experience in market access, and increased sophistication among both physicians and payers in managing the reimbursement process.